What is it about?
Benign prostatic hyperplasia (BPH) and prostate cancer are predominantly influenced by androgens, with dihydrotestosterone (DHT), a potent metabolite of testosterone (T), playing a critical role in their progression. The enzyme 5α-reductase (5α-R) converts testosterone into DHT, which significantly enhances cell proliferation. Consequently, targeting this enzyme is a promising strategy for developing effective treatments for these serious conditions. This study investigates the biological activity of three innovative series of pregnenolone derivatives, assessing their potential as 5α-R inhibitors and antiandrogens in androgen-dependent tissues. Remarkably, several newly synthesized derivatives have shown strong inhibition of type 2 5α-R activity, leading to a notable reduction in prostate weight in a T-treated castrated hamster model of benign prostatic hyperplasia. These findings highlight the potential of these compounds to advance therapeutic options for managing benign prostatic hyperplasia and prostate cancer.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The novel pregnenolone derivatives show potential to advance therapeutic options for managing benign prostatic hyperplasia and prostate cancer.
Perspectives
These compounds should be produced on a larger scale to conduct clinical trials.
Dr Marisa Cabeza
Universidad Autónoma Metropolitana-Xochimilco
Read the Original
This page is a summary of: Effect of Pregnenolone Derivatives on the Selective Inhibition of 5α-Reductase 2 Activity, Current Enzyme Inhibition, March 2020, Bentham Science Publishers,
DOI: 10.2174/1573408015666191105144355.
You can read the full text:
Contributors
The following have contributed to this page
